FDA Investigators Explain How to Avoid Enforcement Actions
This article was originally published in The Gold Sheet
Pharmaceutical manufacturers need to take a more proactive approach to GMP compliance to ward off potential enforcement actions such as Form 483 reports, warning letters and withhold recommendations, FDA investigators told a recent conference. The key: No surprises.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.